Accuprobe Healthcare And Diagnostics Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 9.62%
- Profit Growth -53.45%
- Ebitda -43.93%
- Net Worth 17.28%
- Total Assets 11.56%
About Accuprobe Healthcare And Diagnostics
Accuprobe Healthcare And Diagnostics Private Limited (AHADPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 March 2015 (Nine years and 11 months 26 days old ). Its registered office is in East Delhi, Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Puri, Anurag Kashyap, Sachindra Nath, and One other member serve as directors at the Company.
Company Details
- Location
East Delhi, Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74999DL2015PTC277429
- Company No.
277429
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Mar 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Accuprobe Healthcare And Diagnostics?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Puri  | Director | 03-Mar-2015 | Current |
| Sachindra Nath | Director | 03-Mar-2015 | Current |
| Prashant Goyal | Director | 03-Mar-2015 | Current |
| Anurag Kashyap | Director | 03-Mar-2015 | Current |
Financial Performance of Accuprobe Healthcare And Diagnostics.
Accuprobe Healthcare And Diagnostics Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 9.62% increase. The company also saw a substantial fall in profitability, with a 53.45% decrease in profit. The company's net worth Soared by an impressive increase of 17.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Accuprobe Healthcare And Diagnostics?
In 2023, Accuprobe Healthcare And Diagnostics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Accuprobe Healthcare And Diagnostics?
Accuprobe Healthcare And Diagnostics has a workforce of 283 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Accuprobe Healthcare And Diagnostics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Accuprobe Healthcare And Diagnostics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.